Hansa Biopharma (HNSA) Stock Overview
A biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
HNSA Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Hansa Biopharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 32.68 |
| 52 Week High | SEK 42.98 |
| 52 Week Low | SEK 20.80 |
| Beta | 1.64 |
| 1 Month Change | 10.03% |
| 3 Month Change | 0.12% |
| 1 Year Change | 45.12% |
| 3 Year Change | -38.80% |
| 5 Year Change | -79.70% |
| Change since IPO | 197.09% |
Recent News & Updates
Recent updates
Hansa Biopharma AB (publ) (STO:HNSA) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
Nov 16
Hansa Biopharma AB (publ) (STO:HNSA) Stocks Shoot Up 29% But Its P/S Still Looks Reasonable
Oct 02
Idefirix Expansion And Clinical Trials Will Open New Markets
Expanding Idefirix in Europe and securing reimbursements may enhance revenue by increasing market penetration and adoption rates.Downgrade: Here's How Analysts See Hansa Biopharma AB (publ) (STO:HNSA) Performing In The Near Term
Feb 12Hansa Biopharma AB (publ) (STO:HNSA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Feb 09It's Down 26% But Hansa Biopharma AB (publ) (STO:HNSA) Could Be Riskier Than It Looks
Feb 08Hansa Biopharma AB (publ) (STO:HNSA) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Dec 22It's Down 30% But Hansa Biopharma AB (publ) (STO:HNSA) Could Be Riskier Than It Looks
Nov 07Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Oct 20Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%
Aug 24Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%
Jul 23Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Jul 21Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package
Jun 21Hansa Biopharma AB (publ) (STO:HNSA) Looks Just Right With A 32% Price Jump
May 21Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates
Apr 05Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report
Feb 07Shareholder Returns
| HNSA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 2.5% | 4.2% | 2.6% |
| 1Y | 45.1% | 27.5% | 22.4% |
Return vs Industry: HNSA exceeded the Swedish Biotechs industry which returned 27.5% over the past year.
Return vs Market: HNSA exceeded the Swedish Market which returned 22.4% over the past year.
Price Volatility
| HNSA volatility | |
|---|---|
| HNSA Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in SE Market | 12.7% |
| 10% least volatile stocks in SE Market | 3.7% |
Stable Share Price: HNSA has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: HNSA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 133 | Renee Aguiar-Lucander | www.hansabiopharma.com |
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis.
Hansa Biopharma AB (publ) Fundamentals Summary
| HNSA fundamental statistics | |
|---|---|
| Market cap | SEK 3.33b |
| Earnings (TTM) | -SEK 534.11m |
| Revenue (TTM) | SEK 222.27m |
Is HNSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HNSA income statement (TTM) | |
|---|---|
| Revenue | SEK 222.27m |
| Cost of Revenue | SEK 83.56m |
| Gross Profit | SEK 138.71m |
| Other Expenses | SEK 672.82m |
| Earnings | -SEK 534.11m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 23, 2026
| Earnings per share (EPS) | -5.25 |
| Gross Margin | 62.41% |
| Net Profit Margin | -240.30% |
| Debt/Equity Ratio | -1,042.1% |
How did HNSA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/07 09:17 |
| End of Day Share Price | 2026/04/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hansa Biopharma AB (publ) is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Christian Lee | ABG Sundal Collier Sponsored |
| Madhu Kumar | B. Riley Securities, Inc. |